Xeris Pharmaceuticals | XERS - Selling And Administration Expenses


Xeris Pharmaceuticals reported $46.46M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Celltrion KRW 249.98B 16.36B Sep/2025
Cspc Pharmaceutical CNY 1.97B 404.66M Sep/2025
Deva Holding AS TRY 462.26M 48.18M Sep/2023
Dianthus Therapeutics USD 8.2M 669K Sep/2025
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Kangmei Pharma CNY 274.41M 15.05M Sep/2025
Knight Therapeutics CAD 31.02M 464K Sep/2025
Laboratorios Farma EUR 35.32M 2.75M Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 2.84M 4.19M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neuren Pharmaceuticals AUD 3.74M 2.5M Dec/2025
Organigram Holdings CAD 8.86M 499K Sep/2025
Ovoca Bio EUR 2.96M 8K Jun/2022
Pacira USD 91.87M 70K Dec/2025
Perrigo USD 255.9M 10.2M Dec/2025
Pharma Mar EUR 17.31M 3.6M Dec/2025
Qiagen NV USD 153.88M 10.77M Dec/2025
Sartorius EUR 218.7M 6.5M Sep/2025
Sino Biopharmaceutical CNY 7.54B 2.23B Jun/2025
Supernus Pharmaceuticals USD 122.39M 57.29M Dec/2025
Tilray USD 24.85M 1.7M Sep/2025
Zz Pientze Pharmaceu CNY 171.91M 343.2M Sep/2025